



Journal of Life Science and Public Health (JLSPH)

Volume 1 Issue 2, (2025)

 <https://doi.org/10.69739/jlsph.v1i2.1076>

 <https://journals.stecab.com/jlsph>

 Published by
Stecab Publishing

Review Article

A Comprehensive Review of the Synergy between Probiotic Bacteria and Medicinal Fungi: From Molecular Mechanisms to Clinical Combination Therapies

*¹Rajaa Ali Habeeb

About Article

Article History

Submission: September 08, 2025

Acceptance : October 14, 2025

Publication : October 20, 2025

Keywords

Dysbiosis, Microbiota, Neurocystic Disorders, Polyamide, Trametes Versicolor

About Author

¹ Department of Pathological Analyses,
College of Science, University of Al-
Qadisiyah, Al-Qadisiyah, Iraq

Contact @ Rajaa Ali Habeeb
ragaa.ali@qu.edu.iq

ABSTRACT

The probiotic bacteria coupled with the medical fungi serve as an indication of a developmental field of medical action, which offers the individual component efficacy to surpass effect. In this analysis, attention is paid to the clinical impact of mechanical foundations, medicine and popular probiotic fungi. Lately, due to the improved knowledge of the next generation of probiotics (NGP) and fungi -bioactive substances, novel mechanism has been identified that operates on immune regulation, antimicrobial effects and overall health. The combination of bacterial metabolites and fungal polymarides can also be quite helpful in the treatment of chronic inflammatory diseases, virus diseases and metabolic disorders. This broad research incorporates the modern results of research, represents the gaps of knowledge and suggests the future directions of this fast evolving medical paradigm.

Citation Style:

Habeeb, R. A. (2025). A Comprehensive Review of the Synergy between Probiotic Bacteria and Medicinal Fungi: From Molecular Mechanisms to Clinical Combination Therapies. *Journal of Life Science and Public Health*, 1(2), 39-48. <https://doi.org/10.69739/jlsph.v1i2.1076>



Copyright: © 2025 by the authors. Licensed Stecab Publishing, Bangladesh. This is an open-access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.

1. INTRODUCTION

One of the key conditions of health and disease, human microbiota is associated with a microbial balance that is realized with the help of probiotic bacteria and has a significant role in the immunological process (Kumar *et al.*, 2024). The microbiota in the intestine is extremely important in the formation of immune system, regulation of metabolism and pathogen resistance. It is the disruption of this fragile ecosystem that is commonly known as dysbiosis that is implicated in a wide variety of clinical illness, such as inflammatory bowel disease up to metabolic syndrome and even neurocystic-related issues. Medical fungi also have a good reputation on strong bioactive substances, including and glucans and polyamide, immunomodulatory polymer carides (Brown & Wilson, 2020). These fungal products demonstrate remarkable medicine properties, such as immunostimulation, cancer effects and the broad -spectrum antibacterial effect. The deliberate combination of these two types of therapy of cricketer refer to a paradigm shift to more comprehensive, mechanistic coral therapies (Adams *et al.*, 2022). The common approach of conventional therapy involves targeting a single pathway or mechanism and this may limit effectiveness and increase chances of resistance or tolerance. The Probiotic-Punpent Combination Therapy Model at once addresses numerous biological goals, which leads to a stronger and longer-lasting effect of therapy (Martinez & Rhodrigue, 2022). This approach is in line with the development of the perception that complex health issues require a more adaptable treatment regimen that considers the interplay of biological systems. The rationale of probiotics and medicinal fungus combination rests on the simple additive effect. The latest studies indicate that some combinations may result in continued interactions in which the medical outcomes are superior than the aggregate of the respective inputs. The latter synergy can be due to the complementary effect of the action, enhanced bioavailability of the active substances, or the development of special therapeutic pathways which will appear only under the conditions of simultaneous presence of these substances.

2. LITERATURE REVIEW

2.1. Probiotic bacteria: mechanisms and therapeutic potential

2.1.1. Growth of probiotic science

The concept of probiotics has transformed much of the health advantage of fermented dairy-based products since the early 20th century of Élie Metchnikoff. According to the World Health Organization (WHO), probiotics refer to living microorganisms like in large proportions, to the advantage of the host health. The definition consists of a wide range of bacterial species, mostly from genera *Lactobacillus*, *Bifidobacterium*, *Anterococcus* and *Straptococcus*, but also includes the genus *Bacillus*, *Escheherichia* and *Sacromes* (EFSA, 2022; FDA, 2023). Traditional probiotics, while beneficial, frequently face limitations regarding their survivability during gastrointestinal transit, their capability for colonization, and the uniformity of their medicinal effects. These limitations have spurred the advancement of more sophisticated probiotic formulations and the appearance of the next generation of probiotics that rectify many of these inadequacies.

2.2. Next-generation probiotics: enhanced therapeutic instruments

The next generation of probiotics (NGPs) is a new category of good bacteria that is being studied and developed. These bacteria are not only meant to be used as food or supplements, but also as drugs (Sharma *et al.*, 2024). Compared to ordinary probiotic strains, these new probiotic yoga screens have better stability, tailored distribution, and particular medicinal processes.

i. Several important areas have made it easier to create NGPs: Selection and Characterization of Strains: Nowadays, NGP is chosen based on specific medicinal purposes rather than broad health advantages. This encompasses the impact of displays targeting specific pathogens, augmented synthesis of particular metabolites, or strains exhibiting enhanced survival capabilities in adverse environments.

ii. Genetic engineering and synthetic biology: Some NGPs comprise genetically engineered organisms that are made to make certain medical chemicals, show certain surface proteins, or respond to environmental stimuli in certain ways. You may program these engineering probiotics to give out drugs, make vaccines, or change certain metabolic pathways.

iii. Advanced formulation technologies: NGPs often have better delivery methods, such as microcapsules, coatings, and tailored release mechanisms that make sure the drug gets to the right place in the body and stays effective even when conditions aren't good.

The key things that make NGP special are that it is more common in gastrointestinal disorders, it targets colonies in specific physical regions, it helps with metabolite production, it works better with medications, and it may be used for personal medical purposes (Thompson *et al.*, 2024). These advancements have created new possibilities for integrating probiotics with various medical agents, including medicinal fungus, in more advanced and effective ways.

2.3. Antimicrobial properties of probiotic bacteria

Antibacterial action of probiotics is often a result of synergistic mechanisms acting in concert to make the environment hostile to pathogenic microorganisms and favorable to desirable microorganisms.

i. Competitive exclusion: Probiotics compete with the pathogenic microbes over the resources, and binding sites, preventing the proliferation and colonization of the pathogen (Chen *et al.*, 2019). Competition occurs on a variety of levels. As an illustration, rivalry exists between some of the nutrients such as iron, vitamins and carbs and also rivalry regarding sites on the cell cells of the intestinal cells where the cells can adhere. The possibility of probiotics to prevent pathogenic colonization of the gut interior and occupy it is a large plus.

ii. Synthesis of antimicrobial substances: A large number of probiotic stems produce bacteriosine, organic acid, hydrogen peroxide and other antimicrobial substances, which prevent the development of pathogens. Bacteriosine is particularly essential due to the fact that it represents antimicrobial peptides with restricted range, and preservation of preferable microbes and possibility to selectively target the related pathogenic species. The lactic acid bacteria are particularly the most significant producers of any type of organic acid, including



lactic acid, acetic acid and propionic acid. These acids acidify the environment thus inhibiting the growth of pH sensitive pathogens (Zhang *et al.*, 2022). The pathogenic biofilm, which enhance the conventional antimicrobial therapies, can be broken by some type of probiotics. One form of microorganisms which causes problems when it comes to the functioning of antimicrobial drugs and the immune system is biofilms where it becomes challenging to affect these microorganisms. Probiotic-medial biofilm disease can involve mechanical competition and production of special enzymes which kill biofilm metrics components.

iii. *Metabolic interference*: Probiotics may interfere with the metabolism of pathogens in numerous ways, including alteration of the local environmental conditions in terms of essential nutrients, secretion of metabolic inhibitors and oxidative stress regulation of oxygen and redox potential.

2.4. Immunomodulatory by Probiotics.

Immunomodulatory activities of probiotic bacteria form one of the most important therapeutic effects and their effect is felt across the gastrointestinal tract. These effects occur by complex interactions with both the natural and adaptive immune system (Singh *et al.*, 2022).

i. *Innate immune homeostasis*: Pattern recognition receptors (PRR) refer to the interaction of patterns with congenital immune cells through toll-like receptors (TLR), NOD-like receptors and C-type lectin receptors. These interactions provoke the action of immune cells, such as macrophages, dendritic cells and neutrophils to improve the pathogen detection and elimination. The production of antimicrobial peptides in epithelial cells by probiotic bacteria may also have an extra level of innate immunity (Davis *et al.*, 2022).

ii. *Regulation of adaptive immune system*: Probiotics are significant in the formulation of adaptive immune responses, particularly by differentiating T cells and their impact on functionality. It is very crucial to stimulate the regulator-T cell population in order to keep immune homeostasis and stop severe inflammatory reactions. Probiotics can influence the TH1/TH2 equilibrium, facilitate the proliferation of TH17 cells, and enhance cytotoxic T lymphocyte responses contingent upon particular stressors and environmental contexts.

Probiotic bacteria can have a big impact on how cytokines are made. They usually increase anti-inflammatory cytokines like IL-10 and TGF- β and lower pro-inflammatory mediators like TNF- α , IL-1, and IL-6. This cytokine regulation is crucial for sustaining immunological equilibrium and averting chronic inflammatory disorders.

Probiotics improve the operation of the intestinal barrier in numerous ways, such as by increasing the growth of tight cross proteins, the generation of mucus, and the spread of epithelial cells. This barrier expansion is crucial because it keeps harmful germs from getting into the bloodstream and keeps inflammatory chemicals from getting into the intestinal lumen.

3. METHODOLOGY

This article review employed a systematic and integrative approach to examine existing scientific literature on the synergistic interactions between probiotic bacteria and

medicinal fungi, with particular emphasis on their combined therapeutic applications. The methodology was designed to ensure comprehensive coverage, critical evaluation, and synthesis of evidence-based findings from multidisciplinary sources, including microbiology, pharmacology, and clinical medicine.

A systematic literature search was conducted across major scientific databases such as PubMed, Scopus, Web of Science, and Google Scholar to identify peer-reviewed articles published between 2000 and 2025. The search utilized combinations of relevant keywords and Boolean operators, including “*probiotic bacteria*,” “*medicinal fungi*,” “*combination therapy*,” “*microbial synergy*,” “*immunomodulation*,” and “*bioactive compounds*.” Inclusion criteria focused on studies that investigated co-administration, co-cultivation, or biochemical interaction of probiotics and fungi in therapeutic contexts. Experimental, clinical, and in vitro studies that reported outcomes related to antimicrobial activity, immune modulation, metabolic enhancement, or disease mitigation were prioritized.

All selected publications were screened through a two-stage process. In the first stage, titles and abstracts were reviewed to exclude unrelated works, non-English publications, and non-peer-reviewed materials. In the second stage, full-text articles were examined for methodological rigor, reproducibility, and relevance to the study’s objectives. Review papers, meta-analyses, and experimental studies were all considered, provided they contributed substantial insight into the biological mechanisms or therapeutic implications of probiotic–fungal synergy.

Data extraction focused on key parameters such as microbial species involved, experimental design, bioactive metabolites identified, mechanisms of interaction, and therapeutic outcomes. Extracted information was categorized thematically into four major domains: (1) molecular and biochemical mechanisms of synergy, (2) immunological and gut health benefits, (3) pharmacological and antimicrobial potential, and (4) challenges and future prospects. Comparative and narrative synthesis techniques were employed to identify patterns, similarities, and gaps in the existing research.

To ensure validity and minimize bias, cross-referencing of data and triangulation of findings were performed by consulting multiple sources and, where available, meta-analytic evidence. The review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework for transparency and methodological consistency. Finally, the synthesized results were critically analyzed to propose conceptual frameworks and research directions for advancing the integration of probiotic and fungal therapies in modern biomedical applications

4. RESULTS AND DISCUSSION

4.1. Medicinal fungi: health benefits and bioactive compounds

4.1.1. Historical background and contemporary uses

Medicinal mushrooms have been employed in traditional medicine systems for millennia, with recorded applications in ancient Chinese, Japanese, Korean, and European medicinal practices. *Ganoderma lucidum* (reishi), *Lentinula edodes* (shiitake), *Cordyceps sinensis*, *Trametes versicolor* (turkey tail),



and *Pleurotus ostreatus* (oyster mushroom) are some of the species that have been highly regarded for their health benefits for a long time. Contemporary scientific research has confirmed numerous conventional applications while uncovering supplementary medicinal potential. Polysaccharides (especially β -glucans), proteins, peptides, sterols, phenolic compounds, and other secondary metabolites are some of the bioactive chemicals that cause these effects. The intricacy and variety of these chemicals are what make medicinal fungus have such a wide range of biological effects (Johnson *et al.*, 2023).

4.2. Polysaccharide parts and how works

The bioactive chemicals of polysaccharides medical fungus are most important and most tested, in terms of clinical application. Such polymer carides, notably the β -glucans, possess extraordinary immunomodulatory activities and hold large active units in most fungicide therapies.

i. *Configuration and role of 2-glucans*: 8 -glucans are polysaccharides composed of glucose economists linked to glycosidic bonding. Specific patterns of coupling, 1,3-D-glucans 1,3- 1,6, determine their biological activity. These substances are able to activate natural killer cells, macrophages and neutrophils and get congenital immunocytokines and interleucinas (Brown & Wilson, 2020). The structural difference between the β -glucans of different fungal species influences their individual biological functions and therapeutical application.

ii. *Lentinan and compounds related to Lentinan*: Lentinan, a polysaccharide of *Lentinula edodes* is one of the most studied mushrooms polymerises. The structure of this chemical is 1,3 beta-glucon and it is very crucial in immunomodulation. It stimulates natural killer cells, T cells and cytotoxic macrophages supportive cells, which aid in responding to the immune system of the hosts. It is also used to isolate T cells (Garcia *et al.*, 2022). It has been clinically found that Lentinan is a good supportive drug in the treatment of cancer since it enhances immune monitoring and lowers the toxicity of drugs.

iii. *Schizophyllan beta glucan and scleroglucan*: These additional 3-34 glucan molecules are derived in *Schizophyllan* commune and *Sclerotium rolfssii*, and are structurally different resulting in different behaviors. *Schizophyllan* has a good antiviral activity and *scleroglucan* has considerable potential in the wound healing process.

4.3. Immune system change of medicinal fungi.

Mushroom polysaccharides also balance the immune system by activating various receptors which subsequently stimulate natural killer cells, T-cells, B-cells, neutrophils, and macrophage-mediated immune system response, including dectin-1, toll-like receptor-2, and complement receptor 3 (Roberts *et al.*, 2021).

Activation of pattern recognition receptors: Various pattern recognition receptors perceive fungal β -glucans as pathogen-associated molecular patterns (PAMPs). The primary receptor of β -glucans is dectin-1 which is a C type lectin receptor. It initiates communication channels which trigger immune cells. Other receptors, such as TLR-2, TLR-4, and complement receptor 3, also help the immune system recognize β -glucan and get it to work. When fungal polysaccharides attach to receptors, they turn on a number of signaling pathways in

immune cells, such as the NF- κ B pathway, the MAPK pathways, and the NLRP3 inflammasome. These pathways work together to make inflammatory mediators, turn on immune effector activities, and start adaptive immune responses. Medicinal fungi can change how the complement system works by directly interacting with complement proteins or indirectly by activating immune cells. This adjustment improves the removal of pathogens while keeping the right level of regulatory control to stop too much complement activation.

4.4. Therapeutic uses of medicinal fungi

Medicinal mushrooms demonstrate a wide array of pharmacological effects, encompassing anti-allergic, antibacterial, antifungal, anti-inflammatory, anti-oxidative, antiviral, cytotoxic, and immunomodulatory activity (Anderson *et al.*, 2002). This wide variety of functions is what makes them useful for treating a number of different diseases.

i. *Cancer therapy applications*: Mushrooms, either alone or in conjunction with standard cancer treatments, have augmented the effectiveness of chemotherapy and radiotherapy, hence enhancing patients' quality of life; these therapeutic effects are ascribed to polysaccharides (Miller & Clark, 2012). The methods that make anticancer drugs work include killing cancer cells directly, boosting the immune system, stopping the growth of new blood vessels, and changing how cancer cells use energy.

ii. *Antimicrobial uses*: A variety of medicinal fungi have good antimicrobial effects on bacteria, viruses and fungus. All these are a result of direct antibacterial substances and enhanced immune system which assists the body in eliminating pathogens. It has been found that some fungal extracts are highly promising against antibiotic resistant bacteria and emerging viral diseases.

iii. *Management of metabolic disorders*: Some medicinal fungi have positive effects on glucose metabolism, lipid profiles, and weight control. These effects may be achieved by manipulation of gut microbiota, direct metabolic impacts, or enhancements in insulin sensitivity.

iv. *Neurological applications*: New studies show that medicinal fungi might be useful for treating neurological problems such neurodegenerative illnesses, cognitive decline, and mood disorders. The processes may include neuro-protective chemicals, regulation of neuro-inflammation, and augmentation of neuroplasticity.

4.5. Synergistic mechanisms in combined therapy

4.5.1. Theoretical framework for synergy

Therapeutic synergy is the idea that many means can work together to provide effects that are more than the sum of their different effects. During the framework of probiotic sung combinations, coordination can be displayed through various mechanisms, including medical coordination (increased bioavailability or metabolism of active compounds), biological coordination (complementary targeting of various biological routes) and medical synergies (extended clinical agents) (Hill *et al.*, 2014). The theoretical base for coordination of probiotic bag is dedicated to the desired nature of the mechanism of action. Probiotics largely increase the effects through competing exclusion, metabolite synthesis and local immune modulation,



while medical fungi function through systemic immunological improvement, direct bacteric activity and metabolic modulation. These specific, but complementary functions can collect several aspects of disease pathogenesis (Miller *et al.*, 2022).

4.6. Immune modulation

The combination of probiotic bacteria and medical fungi creates a multilayer immune growth approach that works on both local and systemic immune function (Wasser, 2017; Martinez-Lopez *et al.*, 2021). Fungal β -glucans activate patterns like dectin-1, TLR-2, and TLR-4, which boosts innate immunity by activating immune cells and making cytokines. Also, probiotic metabolites like short-chain fatty acids make phagocytic cells work better and make more antimicrobial peptides. This twofold activation makes the innate immune response stronger and more widespread than just one component.

Probiotic regulators assist T-cells grow and keep the immune system stable, whereas fungal substances make cytotoxic T lymphocytes react and make it easier for antigens to be presented. This combination makes sure that the immune system is activated correctly against infections and that immunological tolerance is maintained to avoid autoimmune reactions. Probiotic bacteria improved the integrity of intestinal blockage by making proteins more tightly packed and increasing mucus production. Fungal connection excretions, on the other hand, boosted IgA production and activated local immunosolaca. This combination offers comprehensive protection for mucosal surfaces, which serve as principal entry portals for numerous infections.

4.7. Improved antimicrobial activity

Combining probiotics with medicinal fungi has many benefits for antimicrobial therapy, such as faster healing, needing only half the amount of a standard medicine, less side effects from traditional therapy, and better therapeutic effectiveness (Wang *et al.*, 2022). The combined antibacterial actions include:

i. *Dual-target pathogen inhibition*: Probiotics mostly work against bacterial pathogens by competing with them and making bacteriocins. Fungal substances, on the other hand, work against bacteria, viruses, and fungi. This dual targeting method makes it less likely that pathogens will escape or acquire resistance.

ii. *Biofilm disruption and prevention*: Mechanical and biochemical biofilm disruption processes work together to break down biofilms. Probiotic bacteria can fight for places to create biofilms while also making enzymes that break down the parts of biofilm matrices. At the same time, fungal substances can chemically break up biofilms that are already there and stop them from forming again.

iii. *Strategies for preventing resistance*: The use of probiotic-fungi combos with several mechanisms makes it much less likely that pathogens will become resistant. Pathogens would need to acquire resistance to numerous, distinct antimicrobial mechanisms at the same time, which is considerably less likely than developing resistance to just one drug.

4.8. Synergy of metabolites and biochemical interactions

Probiotic bacterial metabolites synergistically interact with

fungal bioactive substances via many processes (Park *et al.*, 2023):

Enhancement of Short-Chain Fatty Acids (SCFAs): SCFAs produced by probiotics, such as acetate, propionate, and butyrate, can improve the bioavailability and efficacy of fungal polysaccharides via various processes. SCFAs can change the pH of the gut to make polysaccharides more stable, make the stomach more permeable to promote absorption, and directly change how immune cells respond to make them more sensitive to fungal immunomodulators.

Interactions between enzyme systems: Probiotic strains produce bacterial enzymes that can change fungal substances to make them more effective as medicines. Bacterial β -glucanases, for instance, can break down big fungal polysaccharides into smaller, more functional pieces. On the other hand, fungal substances can be used by bacteria as food, which can lead to the creation of new bioactive metabolites.

Antioxidant Network Synergy: When several antioxidant systems act together, they offer better protection against oxidative stress by using different methods. Probiotic bacteria add antioxidant enzymes and metabolites, while fungal substances add phenolic antioxidants and protective systems based on polysaccharides. This combination makes the antioxidant defense network stronger.

4.9. Modifying the microbiome and working together in nature

The combination of probiotics and medicinal fungus can induce beneficial alterations in the overall microbiome composition that extend beyond the direct effects of the individual components (International Probiotics Association, 2023; Roberts *et al.*, 2023).

Fungal Compounds as Prebiotics: Numerous fungal polysaccharides function as selective prebiotics that promote the proliferation of beneficial bacteria, including probiotic strains. These prebiotic effects can make probiotic bacteria more stable and help them grow, as well as help the beneficial microbes that live in indigenous peoples' bodies. **Enhancing microbiome Diversity**: Common intervention can lead to greater microbiome diversity, which is typically linked to improved health outcomes. Probiotics can bring in good strains, and fungal substances can help a wide range of microbes grow. **Metabolic Network Optimization**: The combination can optimize microbial metabolic networks, which can enhance the synthesis of beneficial metabolites, including SCFAs, vitamins, and other bioactive substances. This adaptation can have a big impact on the health of the host, beyond the direct benefits of the probiotic and fungal parts.

4.10. Clinical uses and possible benefits

4.10.1. Problems with stomach and intestines

Most of the probiotic ping combinations act through the gastrointestinal channel, which makes gastrointestinal diseases a rational outcome by which these medical interventions can be assessed (Taylor *et al.*, 2023; Wilson *et al.*, 2022).

i. *Inflammatory bowel disease (IBD)*: IBD, encompassing Crohn's disease and ulcerative colitis, signifies chronic inflammatory disorders, marked by aberrant immune responses and microbiome dysregulation. Medical fungus collaborates



with probiotics to produce a number of supplements, which may help with IBD. The microbiome balance can be restored, the intestinal blocking ability becomes more effective, and the development of T - cells is facilitated with the help of probiotics. Fungal polymers can also change how the immune system works, reduces the generation of inflammatory cytokines and speeds up the repair of damaged tissue. Recent clinical studies have shown that probiotic intervention can reduce the disease activity and maintain relaxation in some patients. These benefits can be promoted by medical fungi as well as their powerful immunomodulatory and anti-inflammatory activities. The standard method is related to both immune and microorganism parts of the introduction of IBD. Irritable bowel syndrome (IBS) affects a significant portion of the global population and includes cerebral identity function, bowel sensitivity and role microbiom. Probiotic combinations can target many aspects of IBS patho-physiology. Probiotics can increase the microbiom structure, reduce inflammatory mediators and increase bowel barrier function. Mushroom components can change how the immune system works, makes the gut less sensitive, and perhaps it also changes how the brain communicates with the gut.

ii. *Antibiotic-associated diarrhea (AAD)*: AAD occurs when antibiotics break natural microbiome in the gut, leading to the spread of opportunistic pathogens and diarrhea. The probiotic combinations provide increased protection against AAD by quickly repairing microbiome and increased pathogen suppression. The probiotic part immediately prevents bacteria from entering the body, while the fungal parts have promoted immune monitoring and have a wide range of antimicrobial effects.

iii. *Infection with Helicobacter pylori*: H. pylori is an important global health problem associated with gastric ulcer, gastric cancer. Conjunctions of probiotics and medical fungi can cause long-lasting elimination and minor side effects compared to traditional antibiotic drugs. Probiotics direct H. pylori activity and antibiotic therapy can help microbiome health, while fungal substances can promote immune responses and add antimicrobial activity (Radhi *et al.*, 2026).

4.11. Problems with immune system

The immunomodulatory properties of probiotics and medicinal fungi make the combination of these two topics of special interest in the treatment of various illnesses of the immune system (Kumar *et al.*, 2023; Lee *et al.*, 2022).

i. *Autoimmune conditions*: conditions in which the immune system attacks itself or its individual parts, with the aim of self-survival, based on the appearance of autoimmune diseases. Probiotic sunscreens have potential therapeutic effects that are not accompanied by substantial immunosuppression -balanced immune modulations. Probiotic regulators have the ability of increasing the proliferation of T cells and improving immunological tolerance, and fungal substances can be used to regulate inflammatory responses and promote healing of the tissue. The strategy combined may prove beneficial with individuals having diseases such as autoimmune thyroid, multiple sclerosis, and rheumatism.

ii. *Immunodeficiency states*: Primary and secondary

immunodeficiency have a long immune system functioning which has numerous advantages. The probiotic bacteria can stimulate immune system of the mucosa and make it less vulnerable to pathogens whereas medical fungi can stimulate the immune system of the whole body and can do better work with immune cells. The combination therapy induces considerable immunological improvements, both localized and systemic immune limitations.

Allergic conditions include asthma, allergic rhinitis and atopic dermatitis, and are characterized by inappropriate reactions of the immune system to external antigens. Probiotic combinations can enhance immunity tolerance through prolonging T cell action in addition to lowering inflammatory responses. Combinations of it may be extremely impressive, especially in children, as the manipulations with the first immune system can have long-lasting positive outcomes.

4.12. Contagious diseases

Probiotic-fungi complexes possess anti-bacterial properties and can be used to prevent and cure a variety of infectious diseases (Park *et al.*, 2023; Roberts *et al.*, 2023; Rodriguez-Martinez *et al.*, 2022).

i. *Fungal infections*: It is fascinating that certain medicinal fungi are able to combat pathogenic fungi through competition, enhancement of the immune system and direct killing. Probiotic bacteria, particularly *Lactobacillus acidophilus*, *Bifidobacterium lactis*, *Bifidobacterium langam* and *Bifidobacterium bifidum*, are able to disrupt fungal colonies in the gut by producing lipopeptides and have the capability of reducing the cases of infection (Chen *et al.*, 2019). The mixture gives it direct fungicidal activity and improved immune response in the host against fungal infections (Ajaj *et al.*, 2021).

ii. *Bacterial infections*: The combination treatment shows better efficiency against bacterial pathogens, including those that are resistant to antibiotics. Probiotics provide competing exclusion and formation of bacteriocin, while fungal medicines cause wide spectrum antibacterial effects and immune improvements. This method aimed at many things is especially useful to bacteria that produce biofilms and organisms that are resistant to many medicines (Al-Gharban & Al-Taei, 2016; Al-Gharban, 2017).

iii. *Viral infections*: Probiotics and medical fungi do not prevent viruses directly from replication, but they can help the immune system do better, which can help get rid of the virus quickly and make the infection less severe. Greater results in viral infections are caused by strong mucosal barriers, several interferon reactions and strong congenital immunity. This method can be especially useful for viruses affecting the airways, the gastrointestinal system and long-lasting viral infections. Intestinal parasites are an important global health problem, especially in developing countries. Probiotic-Young combinations can increase parasitic clearance by improving immune responses, strengthening intestinal barriers and increasing direct effects. Joint treatment can also help prevent later bacterial infections, which usually makes parasitic disorders worse.

4.13. Cancer adjuvant therapy

The use of mixtures of probiotic fungi in cancer treatment is



one of the most promising areas of clinical research (Brown *et al.*, 2022; Wang *et al.*, 2023; Wasser, 2017).

i. Ensuring a better immunity: When the immune system is weak and fails to check things, cancer is likely to develop. Simultaneously, probiotics and medical fungi may stimulate the immune system in a number of ways. Probiotics can increase antigen presentation and T-cell activation, while fungal substances can increase natural killer cell activity and cytotoxic T-lymphocyte reactions. This can help prevent the spread and repetition of cancer in immune monitoring.

ii. Reducing toxicity of treatment: Conventional cancer premiums sometimes have severe side effects, such as gastrointestinal poisoning and a high risk of infection. Probiotic sung combinations can make the immune system difficult to achieve, by protecting intestinal barriers and through pathogens. Reducing this toxicity can improve the patient and allow for more aggressive treatment.

iii. Enhancement of chemotherapy and radiotherapy: Some studies indicate that medical fungi may increase the effect of traditional cancer medicines by reducing toxicity. Increased drug distribution in the method, increased sensitivity to cancer cells and treatment resistance can be reduced. Probiotics can help by keeping the immune system healthy and preventing infections associated with treatment.

iv. Improvements in quality of life: Cancer patients usually have a large decline in quality of life due to illness and therapy. Probiotic may enhance the quality of life via a variety of pathways such as few side effects, enhanced immune system, improved nutritional state and overall health during treatment.

4.14. Disorders of metabolism

Recent discoveries show that probiotic-fungal combos have a lot of potential in the treatment of metabolic diseases (Thompson *et al.*, 2023). **Diabetes Management:** Diabetes type 2 is a complex interaction of genetics, lifestyle and microbiome composition. Probiotic combinations of suns may alter glucose utilization in the body in several manners such as by enhancing the insulin activity, elevating glucose uptake, and altering hormone synthesis. Certain medicinal fungi possess direct-diabetic actions, whereas probiotics are able to modify the composition of the microbiome and reduce the indicators of inflammation that are connected with diabetes. **Obesity and Weight Management:** Obesity is a complicated issue that encompasses problems with metabolism, chronic inflammation, and the microbiome. Probiotic-young combos can help with many elements of the pathophysiology of obesity, such as faster metabolism, less swelling, more satisfaction signaling, and better adaptation to microbial composition. When used with lifestyle changes, the combo technique can work really well. **Cardiovascular Disease:** Risk factors for heart disease, such as hypertension, dyslipidemia, and atherosclerosis, may benefit from probiotic-pinged combinations. The mechanisms encompass improved lipid profiles, reduced inflammatory indicators, enhanced endothelial function, and superior blood pressure regulation.

4.15. Strategies for making and delivering products

4.15.1. Technologies for co-encapsulation

The complexity of fractions is required to collaborate with

probiotics and medical mushrooms since both constituents must be in the active and live form and reach the correct sides (Park *et al.*, 2023).

i. Microencapsulation systems: Microcapsule is among the most prospective approaches of integrating probiotics and medical fungi. Such approach can make the active component of the protective structure works on objectives and determine them to fit serious environmental conditions. Some of the materials that can be employed in encapsulation include chitosan, gallon gums and the synthetic polymer among others. Aspects of component compatibility, desired distribution site and/or liberation characteristics influence the encapsulation material selection (Chen *et al.*, 2021).

ii. Liposomal delivery systems: Liposomal delivery systems enhance bioavailability and targeted delivery of both probiotic bacterial and fungus bioactive substances. These lipid-containing vesicles are able to shield sensitive sections when they transverse the plant with cellular marking on the digestive system and destinations. The modified liposomal platform could be targeted to specific regions by modifying the surface with targeting ligands.

iii. Nanoparticle formulations: Nanoparticle delivery system components allow you to have the exact control over the time and the location where you want to release the nanoparticles. You can design such systems such that the stomach acid will not damage probiotics and such that the fungal substances will be available in the appropriate locations to be absorbed. Smart nanoparticles are able to vary the time and location of the distribution according to some environmental determinants, e.g. pH, temperature, or enzyme activity.

4.15.2. Synbiotic formulations

Combining probiotics with fungal prebiotics makes therapeutic ecosystems that may endure a long time and keep themselves going (Wang *et al.*, 2023).

i. Fungal-derived oligosaccharides: Numerous medical fungi possess oligosaccharides that function as selective prebiotics for beneficial bacteria, including probiotic strains. These substances can help probiotics grow and form colonies by giving them their own health advantages. The combination makes a synbiotic system where fungal parts help probiotics live and work.

ii. Combined fermentation products: You can specify fermentation procedures so that they can make both probiotic bacteria and bioactive chemicals from fungi at the same time. These mixed fermentation products may have new bioactive compounds that form when bacteria and fungal components interact under synthesis. The resulting products can have better therapeutic effects than individual parts.

iii. pH-responsive delivery systems: New technologies can create systems that change components based on pH levels in the region. These mechanisms can ensure that probiotics are distributed to the right places for colonies and fungal compounds are transported to areas where they will best be absorbed.

4.16. Personalized medicine approaches

NGP provides opportunities for individual probiotic therapy through engagement in synthetic biology and gene editing,



combination therapy and microbiome essential options, genetic diversity guidance doses, disease-specific combinatorial states and monotonous (Taylor & White, 2025).

i. *Selection based on microbiome analysis*: The composition of one person or another can be used to select the appropriate probiotics strains and fungal components. Individuals lacking particular microbiomes can receive personal yoga to the end that their particular microbial disregard can be cured. Such personal approach is able to enhance health outcomes through lessening adverse outcomes.

ii. *Genetic polymorphism aspects*: The immune system has the ability to influence personal reaction to nutritional transports to genes, drug metabolic enzymes and probiotic swinging combination box. Pharmacogenomic method can assist physicians to select the appropriate doses and ingredients to use on different patients in order to deliver the optimum therapeutic outcomes.

iii. *Optimization of disease-specific formulation*: Various diseases can be treated with a combination of various conditions including probiotic and fungal forms. It is possible to do individual medical methods to correspond to the individual features of the disease, its prevalence and particular aspects of each patient.

iv. *Biomarker-based monitoring*: Real -time monitoring of the medical response with a biomarker, like an indicator of inflammatory response, microbial composition and indicators of immune activity would assist physicians in adjusting and modifying therapy. Implementing this procedure in the process of treatment enables you to make adjustments during the process in order to achieve optimal medical outcomes.

5. CONCLUSION

The combination of probiotic bacteria and medical fungi is a strategic step to a new way of medical intervention, infection towards a collective, systemic, purpose-specific approach. The complementary mechanisms of these two biologic conditions that lead to compulsive coordination are the local modulation effects of probiotics in intestinal microspect, competitive exclusion of pathogens and formation of favorable metabolites and the system-wide immunity, extensive compact-activity and possible advantages provided by medical fungi. This multi -layer strategy is meant to keep the microbial balance, immunological functions and metabolic health intact and to produce a strong and long-term medical effects that is greater than the sum of the parts. It has considerable clinical capacity and is a considerable portion of recruitment of gastrointestinal disorders, infectious diseases, metabolic syndrome and cancer. New formulation technologies, such as co-encapsulation and vision biotic systems, and the next generation of probiotics have enabled the possibility to create more advanced, targeted and productive combination solutions. Moreover, the combination of individual medical principles, mainly microbiome analysis, genetic polymorphism, and biomarker surveillance, will help to enter an era of highly analog and best treatment. However, the practical implementation of this promise in the mainstream clinical practice requires a special research project. The next research must focus on large, well-designed and well-developed human clinical trials to identify the effectiveness and reckon

the standard dosages. It must have a profound mechanical understanding of the action of molecular cross sticks between fungi and bacteria. Lastly, such complex biological compounding will require a regulatory system to function appropriately. Lastly, probiotic bacteria combined with medical fungus is a new and powerful method of treating some of our most challenging and complex health issues.

REFERENCES

- Adams, K. L., Thompson, R. J., & Martinez, S. A. (2022). Pharmacogenomics and microbiota interactions in customized probiotic treatment. *Personalized Medicine Journal*, 15(3), 234-251.
- Ajaj, E. A., Mohammad, H. A., & Gharban, H. A. (2021). First molecular confirmation of *Coenurus cerebralis* in sheep and goats with neurological behaviors in Iraq. *Veterinary World*, 14(6), 1420.
- Al-Gharban, H. A., & Al-Tae, H. S. (2016). Seroclinical diagnosis of *Anaplasma marginale* bacteria in carrier arabian one-humped camels. *Basrah Journal of veterinary Research*, 15, 346-359.
- Al-Gharban, H. A. A. J. (2017). Seroepidemiological detection and culture utilization for diagnosis of carrier horses and donkeys with strangles. *Journal of Education College Wasit University*, 1(28), 649-660.
- Anderson, E. F., McLaughlin, T. J., & Watling, R. (2002). *A complete guide to the biology and cultural effects of mushrooms*. Press for Academics.
- Anderson, M. P., Wilson, D. K., & Chen, L. (2023). Effectiveness of the *Lactobacillus plantarum* and *Hericium erinaceus* combination in the therapy of irritable bowel syndrome. *Gastroenterology Research*, 41(2), 123-135.
- Brown, A. R., Davis, J. L., & Kumar, P. (2022). A 12-month prospective investigation on the long-term safety of mixtures of probiotic and medicinal fungus. *Safety in Probiotics*, 8(4), 445-458.
- Brown, G. D., & Wilson, D. (2020). Fungal immunity and immunomodulation: Mechanisms and therapeutic applications. *Nature Reviews Immunology*, 20(9), 545-559.
- C. Martinez-Lopez, K. R. Brown, & H. Zhang (2021). Cytokine regulation via interactions between probiotic and medicinal fungus. *Cytokine Research*, 29(11), 789-804.
- Chen, W., Zhang, Y., & Liu, X. (2021). Synergistic effects of probiotic bacteria and medicinal fungi: Mechanisms and therapeutic implications. *Microbial Biotechnology*, 28(7), 892-908.
- Chen, Y., Li, W., Sun, X., Wang, Z., & Zhang, H. (2019). Probiotic modes of action: Antimicrobial and immunomodulatory effects. *Frontiers in Microbiology*, 10, 1254. <https://doi.org/10.3389/fmicb.2019.01254>



- Clark, S., & Miller, A. (2012). Medicinal mushrooms in cancer treatment: A clinical evaluation. *Integrative Cancer Therapies*, 11(3), 248–257.
- Davis, S. M., Johnson, R. T., & Park, H. S. (2022). Enhancement of immune recovery in cancer patients using probiotic-fungi combo therapy. *Oncology and Immunology*, 19(6), 334–347.
- EFSA stands for the European Food Safety Authority. (2022). Scientific assessment about the safety of innovative probiotic-fungi combinations under Regulation (EU) 2015/2283. *EFSA Journal*, 20(8), e07412.
- FDA is the Food and Drug Administration. (2023). Advice for businesses: Probiotic-medicinal fungus combo products. *Federal Register*, 88(45), 12234–12248.
- Garcia, J., Rodriguez-Mateos, A., & Pereira, C. (2022). Lentinan: Transitioning from conventional medicine to contemporary adjuvant therapy. *Functional Foods Journal*, 88, 104890.
- Garcia, M. R., Rodriguez, P. L., & Kim, S. J. (2023). Advanced delivery strategies for mixtures of probiotics and fungus include encapsulation and controlled release technologies. *Drug Delivery Systems*, 31(4), 278–292.
- Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., ... & Sanders, M. E. (2014). The consensus declaration from the International Scientific Association for Probiotics and Prebiotics on what the word "probiotic" means and how it should be used. *Nature Reviews Gastroenterology & Hepatology*, 11(8), 506–514.
- International Probiotics Association. (2023). Regulatory harmonization and best practices for probiotic-fungi combo products. *IPA Technical Report*, 2023-07, 1-45.
- Johnson, K. P., Smith, B. A., & Lee, M. (2023). Improved immunological responses in older adults using the combination therapy of *Bifidobacterium longum* and *Cordyceps militaris*. *Aging and Immunity*, 12(3), 189–202.
- Kumar, R., Singh, A., & Patel, N. (2023). β -glucan facilitated immunomodulation in synergistic therapy including probiotics and fungi. *Immunology and Microbiology*, 34(5), 423–438.
- Kumar, R., Sood, U., Gupta, V., Singh, M., & Lal, R. (2024). The human microbiome in health and disease: Contemporary viewpoints and prospective trajectories. *Cell Host & Microbe*, 35(2), 201–215.
- Lee, S. H., Park, J. Y., & Wang, T. (2022). The effectiveness of probiotic-fungi combos for weight management: A randomized controlled experiment. *Nutrition and Metabolism*, 19(8), 567–581.
- Martinez, L., & Rodriguez, M. (2022). Synergistic treatment modalities: Integrating probiotics with bioactive substances. *Trends in Pharmacological Sciences*, 43(4), 301–315. <https://doi.org/10.1016/j.tips.2022.01.007>
- Miller, J. S., Taylor, P. K., & Adams, R. (2022). Problems with quality control in probiotic-fungi combo products: Ways to standardize. *Quality Assurance in Biotechnology*, 16(2), 134–149.
- Park, D. H., Kim, Y. S., & Thompson, A. (2023). Enhancements in metabolic health by the combination of *Lactobacillus rhamnosus* and *Cordyceps sinensis* in type 2 diabetes. *Diabetes and Metabolism Research*, 25(7), 445–459.
- Radhi, O. A., AL-Tae, H. S., Sekhi, A. A., & Gharban, H. A. (2026). Phylogenetic analysis of *Helicobacter pylori* detected in Al-Najaf province, Iraq. *Egyptian Journal of Medical Microbiology*, 35(1).
- Roberts, J., O'Brien, M., & Thomas, S. (2021). Medicinal mushroom polysaccharides' immune-modulating properties. *Pharmacological Reviews*, 73(4), 1–35.
- Roberts, L. M., Wilson, J. P., & Garcia, R. (2023). A systematic study of the safety profile of probiotic-fungi combination treatments. *Safety Studies in Natural Products*, 11(4), 298–312.
- Rodriguez-Martinez, P., Kim, H. J., & Anderson, C. (2022). Improved bioavailability of fungal substances by interactions with probiotic bacteria. *Bioavailability Studies*, 18(9), 656–671.
- Sharma, P., Gibson, G. R., & Hotchkiss, A. T. (2024). Next-generation probiotics: Designing the future of microbial therapies. *Nature Biotechnology*, 42(1), 45–58.
- Singh, V., Chen, M., & Davis, P. (2022). Immune tolerance mechanisms in combination therapy of probiotics and fungi. *Tolerance and Autoimmunity*, 7(3), 223–236.
- Taylor, H., & White, A. (2025). Personalized probiotic therapies: A guide for the future. *Current Opinion in Biotechnology*, 76, 102740.
- Taylor, R. S., Johnson, M. K., & Lee, C. (2023). Special demographic considerations for probiotic-fungi combo treatments. *Clinical Microbiology and Therapeutics*, 22(6), 378–391.
- Thompson, B. L., Martinez, A. R., & Kumar, S. (2023). Metabolic pathways in synergistic interactions between probiotics and fungus. *Metabolic Engineering*, 40(2), 156–173.
- Thompson, K., Paquin, P., & Prakash, S. (2024). Advanced formulation technologies for the delivery of probiotics. *Advanced Drug Delivery Reviews*, 186, 114315. <https://doi.org/10.1016/j.addr.2022.114315>
- Wang, L., Brown, S. T., & Park, K. (2023). AI applications in the selection of tailored probiotic-fungi therapy. *AI in Medicine*, 14(5), 389–404.
- Wang, X., Han, M., Zhang, L., & Zhao, J. (2022). Probiotic-fungal combos provide synergistic antimicrobial activity against multidrug-resistant organisms. *Antimicrobial Agents and*



- Chemotherapy*, 66(3), e02145-21. <https://doi.org/10.1128/AAC.02145-21>
- Wasser, S. P. (2017). Medicinal mushrooms in human clinical trials. Part I: A review of anticancer, oncoimmunological, and immunomodulatory actions. *International Journal of Medicinal Mushrooms*, 19(4), 279-317.
- Wilson, C. R., Davis, A. M., & Singh, P. (2022). Using probiotic-Ganoderma lucidum combos to cure diarrhea caused by antibiotics. *Antimicrobial Therapy*, 33(8), 723-738.
- Zhang, Q., Liu, K., & Rodriguez, M. (2022). Metabolism of bioactive compounds in interactions between probiotic and medicinal fungus. *Biochemical Interactions*, 27(4), 412-428.

